This website uses cookies

This website uses cookies to improve user experience. By using our website you consent to all cookies in accordance with our Cookie Policy.

Essential cookies enable basic functions and are necessary for the website to function properly.
Statistics cookies collect information anonymously. This information helps us to understand how our visitors use our website.
Marketing cookies are used by third parties or publishers to display personalized advertisements. They do this by tracking visitors across websites.

Press Release

ITM expands PSMA-617 supply agreement for no-carrier-added Lutetium-177

Future-oriented and long-term alliance with Endocyte for the further expansion of targeted radioligand therapy with no-carrier-added Lutetium-177 for prostate cancer patients.

ITM Isotopen Technologien München AG (ITM), a biotechnology and radiopharmaceutical group of companies announced today, that it has expanded a long-term agreement for the supply of highly pure no-carrier-added (n.c.a.) Lutetium-177 (177Lu), which was originally concluded in 2018 between ITM AG and Endocyte, Inc., a Novartis company. Under the agreement, ITM will provide Endocyte with supply of n.c.a. 177Lu for its investigational 177Lu-PSMA-617 radioligand therapy for patients with metastatic castration-resistant prostate cancer. Pending approval of investigational drug candidate 177Lu-PSMA-617, ITM would continue to provide its proprietary n.c.a. 177Lu during the commercial phase, supporting the scalability and security-of-supply for patients world-wide.

In addition, the parties have agreed that n.c.a. 177Lu supplied by ITM will be used in future pipeline investigations.

Sidonie Golombowski-Daffner, President of Advanced Accelerator Applications, the radioligand business of Novartis, stated: “We believe in the potential of targeted radioligand therapy to transform the lives of patients and aspire to make it broadly available to those in need. This supply agreement supports our future growth and ability to investigate radioligand therapies in a variety of cancers.”

Steffen Schuster, CEO of ITM, commented: "We are very pleased to expand this long-term alliance, which allows us to further expand and support the development and increasing global patient access to targeted radioligand therapies. We are proud to contribute to these treatments by providing our highly pure n.c.a. 177Lu. By 2030, therapeutic radiopharmaceuticals are expected to account for 50% of the nuclear medicine market. Thanks to the extension of the Endocyte supply agreement, we are confident that we can make a significant impact to this growing demand."

                                                                                                  - Ends -


About ITM Isotopen Technologien München
ITM Isotopen Technologien München AG is a privately held biotechnology and radiopharmaceutical group of companies dedicated to the development, production and global supply of targeted diagnostic and therapeutic radiopharmaceuticals and radionuclides for use in cancer treatment. Since its foundation in 2004, ITM and its subsidiaries have established GMP manufacturing and a robust global supply network of innovative, first-in-class medical radionuclides and generator platforms for a new generation of targeted cancer diagnostics and therapies. Furthermore, ITM is developing a proprietary portfolio and growing pipeline of targeted treatments in various stages of clinical development, which address a range of cancers such as neuroendocrine tumors and bone metastases. ITM’s main objectives, together with its scientific, medical and industrial collaboration partners worldwide, are to significantly improve outcomes and quality of life for cancer patients while at the same time reducing side effects and improving health economics through a new generation of Targeted Radionuclide Therapies in Precision Oncology. For more information about ITM, please visit:


Nicola Scharrer
Head of Marketing & Communications
Phone: +49 89 3298986-151
Email: Nicola.Scharrer(at)


ITM Isotopen Technologien München AG
Chairman of the Supervisory Board - Udo J. Vetter, Executive Board - Steffen Schuster (Chairman), Thomas Dürre
Registered Office of the Company - Lichtenbergstr. 1, 85748 Garching – Commercial Register Munich - HRB 154944